<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474539</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-3007</org_study_id>
    <nct_id>NCT00474539</nct_id>
  </id_info>
  <brief_title>Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given
      concomitantly with routine paediatric vaccinations in Spain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series</measure>
    <time_frame>One month after infant series dose (at 5 months of age)</time_frame>
    <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer greater than or equal to (≥) 1:8 along with the corresponding 95% confidence interval (CI) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose</measure>
    <time_frame>One month after infant series dose 2 (at 5 months of age) and one month after toddler dose (at 16 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
    <description>Predefined antibody levels for Diphtheria (0.01 or 0.1 International units [IU]/mL) and Tetanus (0.01 or 0.1 [IU]/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥ 0.35μg/mL in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
    <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
    <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMCs (13vPnC) were calculated for each pneumococcal serotype and timepoint, and 2-sided, 95% CI were constructed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</measure>
    <time_frame>One month after toddler dose (at 16 months of age)</time_frame>
    <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥ 1:8 along with the corresponding 95% confidence interval (CI) are presented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig)(present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (Sev) (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Systemic events (fever [Fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased (Decr) appetite, irritability, increased (Incr) sleep, decreased sleep, hives, use of medication (Meds) to treat symptoms (Sx), and use of medication to prevent symptoms were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Vaccines, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>1 dose at 2,4,6 and 15 months of age</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
    <description>1 dose at 2,4,6 and 15 months of age</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month-old infants

          -  Available for the entire study period

        Exclusion criteria:

          -  Previous vaccination with any vaccine before the start of the study

          -  Known contraindication to vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Spain: infomed@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Almeria</city>
        <zip>4007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almeria</city>
        <zip>4009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almeria</city>
        <zip>4120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>8195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>8930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coruna</city>
        <zip>15270</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coruna</city>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28900</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vigo</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2007</study_first_submitted>
  <study_first_submitted_qc>May 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>January 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2013</results_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Spain from 4 July 2007 to 23 July 2007.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to the inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and combined diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at the 2- and 4-month visits (infant series Dose 2) and one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3). Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and combined DTPa, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix IPV + Hib) at the 15-month visit (toddler dose). Measles, mumps, and rubella vaccine (MMR) was administered without study vaccine at the 12-month visit.</description>
        </group>
        <group group_id="P2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and combined diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at the 2- and 4-month visits (infant series Dose 2) and one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3). Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and combined DTPa, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix IPV + Hib) at the 15-month visit (toddler dose). Measles, mumps, and rubella vaccine (MMR) was administered without study vaccine at the 12-month visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="223">One participant was randomized to 7vPnC, but received 13vPnC.</participants>
                <participants group_id="P2" count="226">One participant was randomized to 7vPnC, but received 13vPnC.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and combined diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at the 2- and 4-month visits (infant series Dose 2) and one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3). Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and combined DTPa, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix IPV + Hib) at the 15-month visit (toddler dose). Measles, mumps, and rubella vaccine (MMR) was administered without study vaccine at the 12-month visit.</description>
        </group>
        <group group_id="B2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and combined diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at the 2- and 4-month visits (infant series Dose 2) and one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3). Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and combined DTPa, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix IPV + Hib) at the 15-month visit (toddler dose). Measles, mumps, and rubella vaccine (MMR) was administered without study vaccine at the 12-month visit.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="219"/>
            <count group_id="B2" value="225"/>
            <count group_id="B3" value="444"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.4"/>
                    <measurement group_id="B2" value="2.0" spread="0.4"/>
                    <measurement group_id="B3" value="2.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series</title>
        <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer greater than or equal to (≥) 1:8 along with the corresponding 95% confidence interval (CI) are presented.</description>
        <time_frame>One month after infant series dose (at 5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate immunoglobulin G (IgG) antibody concentration to the given concomitant vaccine component.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series</title>
          <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer greater than or equal to (≥) 1:8 along with the corresponding 95% confidence interval (CI) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate immunoglobulin G (IgG) antibody concentration to the given concomitant vaccine component.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="95.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99.1" lower_limit="96.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the difference in percentages between the two groups (13vPnC - 7vPnC) at &gt;=1:8 titer was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for immune response induced by NeisVac-C was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) greater than (&gt;) -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig)(present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (Sev) (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2-month visit.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix hexa at the 2-month visit.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 4-month visit.</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix hexa at the 4-month visit.</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa and at the 6-month visit.</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa and at the 6-month visit.</description>
          </group>
          <group group_id="O7">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix-IPV+Hib at the 15-month visit.</description>
          </group>
          <group group_id="O8">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with with NeisVac-C and Infanrix-IPV+Hib at the 15-month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig)(present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (Sev) (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="217"/>
                <count group_id="O4" value="222"/>
                <count group_id="O5" value="214"/>
                <count group_id="O6" value="221"/>
                <count group_id="O7" value="209"/>
                <count group_id="O8" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness-Any (n=199,205,182,180,170,175,164,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="21.4"/>
                    <measurement group_id="O4" value="16.1"/>
                    <measurement group_id="O5" value="10.6"/>
                    <measurement group_id="O6" value="14.3"/>
                    <measurement group_id="O7" value="28.7"/>
                    <measurement group_id="O8" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness-Sig (n=199,200,177,177,167,169,154,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="1.1"/>
                    <measurement group_id="O4" value="4.0"/>
                    <measurement group_id="O5" value="1.2"/>
                    <measurement group_id="O6" value="1.2"/>
                    <measurement group_id="O7" value="2.6"/>
                    <measurement group_id="O8" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Any (n=196,200,182,177,171,170,169,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="14.5"/>
                    <measurement group_id="O3" value="22.0"/>
                    <measurement group_id="O4" value="14.7"/>
                    <measurement group_id="O5" value="23.4"/>
                    <measurement group_id="O6" value="20.0"/>
                    <measurement group_id="O7" value="26.6"/>
                    <measurement group_id="O8" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mild (n=196,200,182,177,171,170,166,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="13.0"/>
                    <measurement group_id="O5" value="20.5"/>
                    <measurement group_id="O6" value="17.1"/>
                    <measurement group_id="O7" value="22.9"/>
                    <measurement group_id="O8" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mod (n=196,196,177,175,166,168,156,163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="2.3"/>
                    <measurement group_id="O4" value="2.3"/>
                    <measurement group_id="O5" value="6.6"/>
                    <measurement group_id="O6" value="6.0"/>
                    <measurement group_id="O7" value="9.0"/>
                    <measurement group_id="O8" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Sev (n=196,196,177,175,166,168,152,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Any (n=197,199,181,180,172,172,170,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="15.1"/>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="20.0"/>
                    <measurement group_id="O5" value="26.7"/>
                    <measurement group_id="O6" value="22.7"/>
                    <measurement group_id="O7" value="30.0"/>
                    <measurement group_id="O8" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mild (n=197,198,180,180,172,171,167,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="14.1"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="19.4"/>
                    <measurement group_id="O5" value="24.4"/>
                    <measurement group_id="O6" value="21.1"/>
                    <measurement group_id="O7" value="28.1"/>
                    <measurement group_id="O8" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mod (n=196,197,178,175,166,169,157,163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="2.2"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="3.6"/>
                    <measurement group_id="O6" value="3.6"/>
                    <measurement group_id="O7" value="9.6"/>
                    <measurement group_id="O8" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Sev (n=196,196,177,175,166,168,152,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.6"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
        <description>Systemic events (fever [Fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased (Decr) appetite, irritability, increased (Incr) sleep, decreased sleep, hives, use of medication (Meds) to treat symptoms (Sx), and use of medication to prevent symptoms were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2-month visit.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix hexa at the 2-month visit.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 4-month visit.</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix hexa at the 4-month visit.</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa and at the 6-month visit.</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa and at the 6-month visit.</description>
          </group>
          <group group_id="O7">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix-IPV+Hib at the 15-month visit.</description>
          </group>
          <group group_id="O8">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with with NeisVac-C and Infanrix-IPV+Hib at the 15-month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
          <description>Systemic events (fever [Fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased (Decr) appetite, irritability, increased (Incr) sleep, decreased sleep, hives, use of medication (Meds) to treat symptoms (Sx), and use of medication to prevent symptoms were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="217"/>
                <count group_id="O4" value="222"/>
                <count group_id="O5" value="214"/>
                <count group_id="O6" value="221"/>
                <count group_id="O7" value="209"/>
                <count group_id="O8" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fv ≥38°C, ≤39°C(n=201,204,181,189,172,176,156,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="32.6"/>
                    <measurement group_id="O4" value="41.8"/>
                    <measurement group_id="O5" value="20.9"/>
                    <measurement group_id="O6" value="29.0"/>
                    <measurement group_id="O7" value="31.4"/>
                    <measurement group_id="O8" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fv &gt;39°C, ≤40°C(n=196,196,177,176,166,168,154,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="1.7"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="3.6"/>
                    <measurement group_id="O6" value="3.0"/>
                    <measurement group_id="O7" value="4.5"/>
                    <measurement group_id="O8" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fv &gt;40°C (n=196,197,177,175,166,168,152,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.7"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decr appetite (n=204,207,189,191,178,178,163,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="46.6"/>
                    <measurement group_id="O4" value="44.0"/>
                    <measurement group_id="O5" value="37.1"/>
                    <measurement group_id="O6" value="36.0"/>
                    <measurement group_id="O7" value="31.9"/>
                    <measurement group_id="O8" value="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=202,211,192,190,179,188,171,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5"/>
                    <measurement group_id="O2" value="49.8"/>
                    <measurement group_id="O3" value="57.3"/>
                    <measurement group_id="O4" value="60.0"/>
                    <measurement group_id="O5" value="43.0"/>
                    <measurement group_id="O6" value="39.4"/>
                    <measurement group_id="O7" value="41.5"/>
                    <measurement group_id="O8" value="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incr sleep (n=204,206,189,187,175,174,162,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7"/>
                    <measurement group_id="O2" value="39.3"/>
                    <measurement group_id="O3" value="39.2"/>
                    <measurement group_id="O4" value="36.4"/>
                    <measurement group_id="O5" value="21.1"/>
                    <measurement group_id="O6" value="27.0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decr sleep (n=196,204,183,187,175,178,162,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="27.5"/>
                    <measurement group_id="O3" value="27.3"/>
                    <measurement group_id="O4" value="27.8"/>
                    <measurement group_id="O5" value="22.9"/>
                    <measurement group_id="O6" value="25.3"/>
                    <measurement group_id="O7" value="19.8"/>
                    <measurement group_id="O8" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds-treat sx (n=205,209,193,197,175,189,165,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="44.5"/>
                    <measurement group_id="O3" value="54.4"/>
                    <measurement group_id="O4" value="57.9"/>
                    <measurement group_id="O5" value="39.4"/>
                    <measurement group_id="O6" value="42.9"/>
                    <measurement group_id="O7" value="50.3"/>
                    <measurement group_id="O8" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds-prevent sx(n=201,210,194,196,177,185,168,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3"/>
                    <measurement group_id="O2" value="45.7"/>
                    <measurement group_id="O3" value="47.9"/>
                    <measurement group_id="O4" value="49.5"/>
                    <measurement group_id="O5" value="44.6"/>
                    <measurement group_id="O6" value="40.5"/>
                    <measurement group_id="O7" value="43.5"/>
                    <measurement group_id="O8" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose</title>
        <time_frame>One month after infant series dose 2 (at 5 months of age) and one month after toddler dose (at 16 months of age)</time_frame>
        <population>The evaluable 2-dose immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2)</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose). MMR was administered without study vaccine at the 12-month visit.</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose). MMR was administered without study vaccine at the 12-month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose</title>
          <population>The evaluable 2-dose immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654.55" lower_limit="557.75" upper_limit="768.16"/>
                    <measurement group_id="O2" value="757.04" lower_limit="648.45" upper_limit="883.81"/>
                    <measurement group_id="O3" value="2573.06" lower_limit="2176.29" upper_limit="3042.16"/>
                    <measurement group_id="O4" value="2098.12" lower_limit="1779.65" upper_limit="2473.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for or immune response induced by NeisVac-C was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for or immune response induced by NeisVac-C was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose</title>
        <description>Predefined antibody levels for Diphtheria (0.01 or 0.1 International units [IU]/mL) and Tetanus (0.01 or 0.1 [IU]/mL).</description>
        <time_frame>One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
        <population>The evaluable 3-dose immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose</title>
          <description>Predefined antibody levels for Diphtheria (0.01 or 0.1 International units [IU]/mL) and Tetanus (0.01 or 0.1 [IU]/mL).</description>
          <population>The evaluable 3-dose immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria ≥0.10 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="95.6" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99.1" lower_limit="96.6" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria ≥0.01 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus ≥0.10 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="92.6" upper_limit="98.7"/>
                    <measurement group_id="O2" value="96.7" lower_limit="93.0" upper_limit="98.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus ≥0.01 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at &gt;=0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at &gt;=0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For tetanus the difference in percentage between the two groups (13vPnC - 7vPnC) at &gt;=0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For tetanus the difference in percentage between the two groups (13vPnC - 7vPnC) at &gt;=0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at &gt;=0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at &gt;=0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For tetanus the difference in percentage between the two groups (13vPnC - 7vPnC) at &gt;=0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For tetanus the difference in percentage between the two groups (13vPnC - 7vPnC) at &gt;=0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose</title>
        <time_frame>One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
        <population>The evaluable 3-dose immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>SParticipants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose</title>
          <population>The evaluable 3-dose immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.69" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.81" upper_limit="1.04"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.63" upper_limit="3.41"/>
                    <measurement group_id="O4" value="3.23" lower_limit="2.88" upper_limit="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.94" upper_limit="1.27"/>
                    <measurement group_id="O2" value="1.20" lower_limit="1.04" upper_limit="1.39"/>
                    <measurement group_id="O3" value="3.29" lower_limit="2.83" upper_limit="3.83"/>
                    <measurement group_id="O4" value="3.28" lower_limit="2.83" upper_limit="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For tetanus the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For tetanus the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥ 0.35μg/mL in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</title>
        <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥ 0.35μg/mL in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</title>
          <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="87.9" upper_limit="95.7"/>
                    <measurement group_id="O2" value="98.5" lower_limit="95.7" upper_limit="99.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="21.8" upper_limit="34.7"/>
                    <measurement group_id="O2" value="94.9" lower_limit="90.9" upper_limit="97.5"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" lower_limit="84.8" upper_limit="93.7"/>
                    <measurement group_id="O2" value="97.0" lower_limit="93.5" upper_limit="98.9"/>
                    <measurement group_id="O3" value="99.3" lower_limit="96.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" lower_limit="86.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="97.0" lower_limit="93.6" upper_limit="98.9"/>
                    <measurement group_id="O3" value="99.4" lower_limit="96.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="83.7" upper_limit="92.9"/>
                    <measurement group_id="O2" value="99.0" lower_limit="96.4" upper_limit="99.9"/>
                    <measurement group_id="O3" value="98.8" lower_limit="95.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.0" lower_limit="96.4" upper_limit="99.9"/>
                    <measurement group_id="O3" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" lower_limit="48.6" upper_limit="62.8"/>
                    <measurement group_id="O2" value="93.0" lower_limit="88.5" upper_limit="96.1"/>
                    <measurement group_id="O3" value="98.1" lower_limit="94.7" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="92.2" upper_limit="98.2"/>
                    <measurement group_id="O2" value="98.5" lower_limit="95.7" upper_limit="99.7"/>
                    <measurement group_id="O3" value="98.8" lower_limit="95.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="67.1" upper_limit="79.9"/>
                    <measurement group_id="O2" value="86.2" lower_limit="80.5" upper_limit="90.7"/>
                    <measurement group_id="O3" value="93.6" lower_limit="88.6" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="80.8" upper_limit="90.8"/>
                    <measurement group_id="O2" value="96.0" lower_limit="92.2" upper_limit="98.2"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="74.6" upper_limit="86.0"/>
                    <measurement group_id="O2" value="99.0" lower_limit="96.4" upper_limit="99.9"/>
                    <measurement group_id="O3" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="90.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="88.4" upper_limit="96.1"/>
                    <measurement group_id="O2" value="99.5" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</title>
        <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMCs (13vPnC) were calculated for each pneumococcal serotype and timepoint, and 2-sided, 95% CI were constructed.</description>
        <time_frame>One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</title>
          <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMCs (13vPnC) were calculated for each pneumococcal serotype and timepoint, and 2-sided, 95% CI were constructed.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" lower_limit="1.35" upper_limit="1.78"/>
                    <measurement group_id="O2" value="2.32" lower_limit="2.08" upper_limit="2.60"/>
                    <measurement group_id="O3" value="3.88" lower_limit="3.42" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.18" upper_limit="0.25"/>
                    <measurement group_id="O2" value="2.59" lower_limit="2.20" upper_limit="3.05"/>
                    <measurement group_id="O3" value="12.25" lower_limit="10.78" upper_limit="13.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.01" upper_limit="1.32"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.35" upper_limit="1.68"/>
                    <measurement group_id="O3" value="2.67" lower_limit="2.34" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.64" upper_limit="2.29"/>
                    <measurement group_id="O2" value="4.51" lower_limit="3.89" upper_limit="5.22"/>
                    <measurement group_id="O3" value="9.82" lower_limit="8.54" upper_limit="11.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" lower_limit="1.11" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.86" lower_limit="1.68" upper_limit="2.07"/>
                    <measurement group_id="O3" value="2.29" lower_limit="2.01" upper_limit="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" lower_limit="2.60" upper_limit="3.41"/>
                    <measurement group_id="O2" value="2.46" lower_limit="2.21" upper_limit="2.74"/>
                    <measurement group_id="O3" value="6.11" lower_limit="5.21" upper_limit="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.34" upper_limit="0.48"/>
                    <measurement group_id="O2" value="1.67" lower_limit="1.44" upper_limit="1.94"/>
                    <measurement group_id="O3" value="3.96" lower_limit="3.43" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="1.61" upper_limit="2.16"/>
                    <measurement group_id="O2" value="2.95" lower_limit="2.61" upper_limit="3.33"/>
                    <measurement group_id="O3" value="4.60" lower_limit="3.94" upper_limit="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.48" upper_limit="0.61"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.76" upper_limit="0.95"/>
                    <measurement group_id="O3" value="1.04" lower_limit="0.91" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.77" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.83" lower_limit="1.62" upper_limit="2.06"/>
                    <measurement group_id="O3" value="3.69" lower_limit="3.26" upper_limit="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.70" upper_limit="0.95"/>
                    <measurement group_id="O2" value="3.08" lower_limit="2.76" upper_limit="3.44"/>
                    <measurement group_id="O3" value="7.71" lower_limit="6.75" upper_limit="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.33" upper_limit="1.71"/>
                    <measurement group_id="O2" value="3.41" lower_limit="3.11" upper_limit="3.74"/>
                    <measurement group_id="O3" value="5.66" lower_limit="4.90" upper_limit="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" lower_limit="1.31" upper_limit="1.76"/>
                    <measurement group_id="O2" value="2.50" lower_limit="2.27" upper_limit="2.75"/>
                    <measurement group_id="O3" value="10.21" lower_limit="8.92" upper_limit="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</title>
        <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥ 1:8 along with the corresponding 95% confidence interval (CI) are presented.</description>
        <time_frame>One month after toddler dose (at 16 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate IgG antibody concentration to the given concomitant vaccine component.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and combined diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at the 2- and 4-month visits (infant series Dose 2) and one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3). Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and combined DTPa, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix IPV + Hib) at the 15-month visit (toddler dose). Measles, mumps, and rubella vaccine (MMR) was administered without study vaccine at the 12-month visit.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and combined diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at the 2- and 4-month visits (infant series Dose 2) and one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3). Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and combined DTPa, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix IPV + Hib) at the 15-month visit (toddler dose). Measles, mumps, and rubella vaccine (MMR) was administered without study vaccine at the 12-month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</title>
          <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥ 1:8 along with the corresponding 95% confidence interval (CI) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate IgG antibody concentration to the given concomitant vaccine component.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.80" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥ 1:8 titer was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for immune response induced by NeisVac-C was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits. Adverse events were collected from dose 1 to approximately one month after dose 3.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits. Adverse events were collected from dose 1 to approximately one month after dose 3.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit. Adverse events were collected from approximately one month after dose 3 to toddler dose.</description>
        </group>
        <group group_id="E4">
          <title>7vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at the 6-month visit. Adverse events were collected from approximately one month after dose 3 to toddler dose.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC Toddler Series</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix-IPV+Hib at the 15-month visit. Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E6">
          <title>7vPnC Toddler Series</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with with NeisVac-C and Infanrix-IPV+Hib at the 15-month visit. Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2) and one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3). Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose). MMR was administered without study vaccine at the 12-month visit. Adverse events were collected for approximately six months after last visit</description>
        </group>
        <group group_id="E8">
          <title>7vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2) and one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3). Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose). MMR was administered without study vaccine at the 12-month visit. Adverse events were collected for approximately six months after last visit</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coleliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchospams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="171" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="179" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Thalassaemia beta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="156" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="169" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="154" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="156" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="152" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="156" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="163" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="178" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="171" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="179" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="162" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="165" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="162" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="166" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lice infestation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cow's milk intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Infantile asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="164" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="172" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="154" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="160" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose;Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="169" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="168" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (any)</description>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (any)</description>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="166" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="163" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="156" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="163" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="152" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="156" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="170" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="169" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="167" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="165" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="157" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="163" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="152" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="156" subjects_at_risk="218"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

